HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Women's Health · Menopause Therapeutic Area Assessment

Intelligence report

Intelligence Report · ~15 min read

Women's Health · Menopause Therapeutic Area Assessment

22 signals · 6 insights · 92 regulatory precedents

Type

Therapeutic Area Assessment

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 65%

Evidence

120 items

Sources

2

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Therapeutic area assessment for Women's Health · Menopause integrates 22 signals, 6 executive insights, and 92 regulatory precedents from the Humanexa intelligence graph. 0 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. signalJun 25, 2026

    UK-wide ENDO1000 Study Aims to Advance Endometriosis Diagnosis and Treatment

    The ENDO1000 study will collect extensive longitudinal data from 3000 individuals with endometriosis to improve diagnosis and treatment.

    View detail
  2. signalJul 23, 2026

    FDA Approval Update for Norethindrone Acetate and Ethinyl Estradiol

    The FDA has granted an Abbreviated New Drug Application (ANDA) approval for a combination product containing Norethindrone Acetate and Ethinyl Estradiol.

    View detail
  3. signalJul 22, 2026

    Study on Focal Shock Wave Therapy for Vulvodynia Shows Promise

    A retrospective observational study is evaluating the effectiveness of a four-session focal shock wave therapy protocol for vulvodynia.

    View detail
  4. signalJul 20, 2026

    FDA Grants Approval for Carboprost Tromethamine ANDA219529

    The FDA has granted approval for the ANDA219529 application for Carboprost Tromethamine submitted by Somerset TherapS LLC.

    View detail
  5. regulatoryJul 23, 2026

    Withdrawn | Cancer Accelerated Approvals

    This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been subsequently withdrawn, and are therefore, no longer FDA-approved.

    View detail
  6. regulatoryJul 23, 2026

    CDER proposes to withdraw approval of TAVNEOS

    Why this matters: illustrates how regulators handled a comparable approval decision relevant to Xiromed; the same agency is already in play for this signal, so precedent weight is higher.

    View detail
  7. regulatoryJul 23, 2026

    FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Why this matters: illustrates how regulators handled a comparable approval decision relevant to Xiromed; the same agency is already in play for this signal, so precedent weight is higher.

    View detail
  8. regulatoryJul 23, 2026

    Verified Clinical Benefit | Cancer Accelerated Approvals

    This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.

    View detail
  9. insightJul 13, 2026

    Emerging Genetic Insights Could Transform Emergency Contraceptive Strategies

    This study highlights the potential for genetic factors to influence the efficacy of emergency contraception, which could lead to a shift towards personalized contraceptive solutions. Pharma companies should be aware of these developments as they may necessitate adjustments in product strategies and marketing approaches. Regulatory context from FDA (FDA Alerts Health Care Providers to Cases of Neurologic Complications from General Anesthesia Linked to Genetic Variant in Patients of Maternal Venezuelan Ancestry) supports the near-term read.

    View detail
  10. insightJul 5, 2026

    FDA Approval of Generic Estradiol and Norethindrone Acetate Alters Competitive Dynamics

    The FDA's approval of ANDA078324 introduces a generic competitor in the hormonal therapy market, which could significantly alter the competitive landscape. Portfolio teams must evaluate the implications for market share and pricing strategies of existing branded products. Regulatory context from FDA (FDA AP — ESTRADIOL AND NORETHINDRONE ACETATE (SUPPL)) supports the near-term read. Assessment grounded in 23 ranked evidence items (4 high-relevance).

    View detail
  11. insightJul 3, 2026

    Targeting Mental Health in Menopausal Hormone Therapy: A Strategic Imperative

    The link between estrogen fluctuations and increased depression in postmenopausal women underscores the need for targeted therapeutic approaches. As the demand for effective menopausal treatments grows, companies must adapt their strategies to develop personalized MHT solutions that address these psychiatric symptoms. Regulatory context from FDA (FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients) supports the near-term read. Assessment grounded in 16 ranked evidence items (6 high-relevance).

    View detail
  12. insightJun 24, 2026

    Lupin's Abbreviated Approval Signals New Competitive Dynamics in Contraception

    Lupin's receipt of Abbreviated Approval for Levonorgestrel and Ethinyl Estradiol signifies a new competitive entrant in the contraceptive market. This development necessitates a strategic reassessment by existing players to maintain market share and respond effectively to Lupin's market strategies. Regulatory context from FDA (FDA AP — LEVONORGESTREL AND ETHINYL ESTRADIOL (SUPPL)) supports the near-term read. Assessment grounded in 30 ranked evidence items (16 high-relevance).

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Executive insights surface 6 risk-calibrated assessments for portfolio review. 92 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 3 companies with active signal exposure for competitive and portfolio shifts.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Withdrawn | Cancer Accelerated Approvals

    95%

    This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been subsequently withdrawn, and are therefore, no longer FDA-approved.

    Source: FDA

    View evidence

  • CDER proposes to withdraw approval of TAVNEOS

    95%

    Why this matters: illustrates how regulators handled a comparable approval decision relevant to Xiromed; the same agency is already in play for this signal, so precedent weight is higher.

    Source: FDA

    View evidence

  • FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    95%

    Why this matters: illustrates how regulators handled a comparable approval decision relevant to Xiromed; the same agency is already in play for this signal, so precedent weight is higher.

    Source: FDA

    View evidence

  • Verified Clinical Benefit | Cancer Accelerated Approvals

    95%

    This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.

    Source: FDA

    View evidence

  • FDA AP — NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE (SUPPL)

    66%

    Application ANDA205049. Sponsor: XIROMED. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ETHINYL ESTRADIOL, NORETHINDRONE ACETATE.

    Source: FDA

    View evidence

  • FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer

    83%

    Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to vulvodynia treatment guidelines.

    Source: FDA

    View evidence

  • Emerging Genetic Insights Could Transform Emergency Contraceptive Strategies

    73%

    This study highlights the potential for genetic factors to influence the efficacy of emergency contraception, which could lead to a shift towards personalized contraceptive solutions. Pharma companies should be aware of these developments as they may necessitate adjustments in product strategies and marketing approaches. Regulatory context from FDA (FDA Alerts Health Care Providers to Cases of Neurologic Complications from General Anesthesia Linked to Genetic Variant in Patients of Maternal Venezuelan Ancestry) supports the near-term read.

    Source: Humanexa Insight

    View evidence

  • FDA Approval of Generic Estradiol and Norethindrone Acetate Alters Competitive Dynamics

    53%

    The FDA's approval of ANDA078324 introduces a generic competitor in the hormonal therapy market, which could significantly alter the competitive landscape. Portfolio teams must evaluate the implications for market share and pricing strategies of existing branded products. Regulatory context from FDA (FDA AP — ESTRADIOL AND NORETHINDRONE ACETATE (SUPPL)) supports the near-term read. Assessment grounded in 23 ranked evidence items (4 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Targeting Mental Health in Menopausal Hormone Therapy: A Strategic Imperative

    62%

    The link between estrogen fluctuations and increased depression in postmenopausal women underscores the need for targeted therapeutic approaches. As the demand for effective menopausal treatments grows, companies must adapt their strategies to develop personalized MHT solutions that address these psychiatric symptoms. Regulatory context from FDA (FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients) supports the near-term read. Assessment grounded in 16 ranked evidence items (6 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Lupin's Abbreviated Approval Signals New Competitive Dynamics in Contraception

    68%

    Lupin's receipt of Abbreviated Approval for Levonorgestrel and Ethinyl Estradiol signifies a new competitive entrant in the contraceptive market. This development necessitates a strategic reassessment by existing players to maintain market share and respond effectively to Lupin's market strategies. Regulatory context from FDA (FDA AP — LEVONORGESTREL AND ETHINYL ESTRADIOL (SUPPL)) supports the near-term read. Assessment grounded in 30 ranked evidence items (16 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Regulatory Developments in Women's Health: Competitive Dynamics and Market Implications

    63%

    The FDA's acceptance of the supplemental application for TWIRLA is a significant regulatory milestone that could strengthen AGILE's competitive position in the contraceptive market. Portfolio teams must evaluate how this development may influence market dynamics and competitor strategies. Regulatory context from FDA (FDA AP — TWIRLA (SUPPL)) supports the near-term read. Assessment grounded in 25 ranked evidence items (4 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Emerging Insights in Women's Health: Impact of Clinical Trials on Treatment Guidelines

    70%

    The findings from this network meta-analysis provide critical insights into the comparative efficacy and safety of minimally invasive treatments for uterine fibroids, which could reshape clinical practices and treatment guidelines. Companies involved in these therapies must stay informed to adapt their strategies in response to evolving treatment preferences. Assessment grounded in 18 ranked evidence items (7 high-relevance).

    Source: Humanexa Insight

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • UK-wide ENDO1000 Study Aims to Advance Endometriosis Diagnosis and Treatment

    Trial Update

  • FDA Approval Update for Norethindrone Acetate and Ethinyl Estradiol

    Regulatory Approval

  • Study on Focal Shock Wave Therapy for Vulvodynia Shows Promise

    Trial Update

  • FDA Grants Approval for Carboprost Tromethamine ANDA219529

    Regulatory Approval

  • Study on Mental Health Outcomes Post-Pregnancy Loss in Denmark

    Trial Update

  • FDA Accepts Supplement for ENDOMETRIN by Ferring

    Regulatory Approval

  • FDA Grants AP Status for ELINEST ANDA091105 by Novast Labs

    Regulatory Approval

  • Study on Genetic Factors Influencing Emergency Contraceptive Efficacy

    Trial Update

Insights

  • Emerging Genetic Insights Could Transform Emergency Contraceptive Strategies

    Women's Health · Contraception

  • FDA Approval of Generic Estradiol and Norethindrone Acetate Alters Competitive Dynamics

    Women's Health · Hormonal Therapy

  • Targeting Mental Health in Menopausal Hormone Therapy: A Strategic Imperative

    Women's Health · Hormone Therapy

  • Lupin's Abbreviated Approval Signals New Competitive Dynamics in Contraception

    Women's Health · Contraception

  • Regulatory Developments in Women's Health: Competitive Dynamics and Market Implications

    Women's Health · Contraceptive

  • Emerging Insights in Women's Health: Impact of Clinical Trials on Treatment Guidelines

    Women's Health · Uterine Fibroids

Companies

  • Teva

    25 signals

  • Lupin

    13 signals

  • Annora Pharma

    6 signals

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.